SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES

• US 20130035670A1
• Filed: 10/08/2012
• Published: 02/07/2013
• Est. Priority Date: 02/03/2005
• Status: Active Grant

• Current Assignee: Intarcia Therapeutics, Inc.
• Original Assignee: Intarcia Therapeutics, Inc.
• Inventors: Rohloff, Catherine M., Chen, Guohua, Luk, Andrew S., Ayer, Rupal A., Houston, Paul R., Desjardin, Michael A., Zamora, Pauline, Lam, Stan
• Granted Patent: US 8,460,694 B2
• Time in Patent Office: Days
• US Class Current: 604/891.1
• CPC Class Codes: A61K 38/043 Kallidins; Bradykinins; Related peptides
• CPC Class Codes: A61K 38/085 Angiotensins
• CPC Class Codes: A61K 38/09 Luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• CPC Class Codes: A61K 38/095 Oxytocins; Vasopressins; Related peptides
• CPC Class Codes: A61K 38/105 Bombesin; Related peptides
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/2242 Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
• CPC Class Codes: A61K 38/225 Calcitonin gene related peptide
• CPC Class Codes: A61K 38/24 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/31 Somatostatins
• CPC Class Codes: A61K 38/35 Corticotropin [ACTH]
• CPC Class Codes: A61K 38/36 Blood coagulation or fibrinolysis factors
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 : Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 : Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/20 : containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 47/26 : Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/32 : Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0004 : Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/0024 : Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/10 : Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61P 1/16 : for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 : of the kidneys
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/14 : for RNA viruses
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: Y10T 29/494 : Fluidic or fluid actuated device making
• CPC Class Codes: Y10T 29/49826 : Assembling or joining

Abstract

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Claims

1-25. -25. (canceled)

26. An implantable osmotic drug delivery device, comprising

a reservoir containing a stable, nonaqueous suspension formulation, the suspension formulation comprising

a particle formulation comprising an active agent and an excipient, wherein the active agent comprises a peptide, polypeptide, or protein, and the excipient comprises methionine or histidine;

and

a nonaqueous, single-phase vehicle consisting essentially of about 10% to about 90% (w/w) polyvinylpyrrolidone and about 90% to about 10% (w/w) benzyl benzoate, wherein the vehicle has a viscosity of between approximately 10,000 poise to approximately 20,000 poise measured at 37°

C.;

a semipermeable membrane;

an osmotic engine;

a piston; and

a diffusion moderator.

27. The implantable osmotic drug delivery device of claim 26, wherein the particle formulation comprises one or more additional excipients.

28. The implantable osmotic drug delivery device of claim 27, wherein the one or more additional excipients are selected from the group consisting of citrate buffer, sucrose, succinate, and dextran.

29. The implantable osmotic drug delivery device of claim 28, wherein the excipients comprise methionine, sucrose, and citrate buffer.

30. The implantable osmotic drug delivery device of claim 26, wherein the single-phase vehicle consists essentially of about 25% to about 75% (w/w) polyvinylpyrrolidone and about 75% to about 25% (w/w) benzyl benzoate.

31. The implantable osmotic drug delivery device of claim 26, wherein the particle formulation is formed by lyophilization, spray-drying, or freeze-drying.

32. The implantable osmotic drug delivery device of claim 26, wherein the particle formulation is present in the suspension formulation in a range from approximately 0.1 to 50% (w/w).

33. The implantable drug delivery device of claim 26, wherein the implantable drug delivery device is not primed before use.

34. A method of making the implantable osmotic drug delivery device of claim 26, the method comprising

assembling the reservoir, the suspension formulation, the semipermeable membrane, the osmotic engine, the piston, and the diffusion moderator to form the implantable osmotic drug delivery device.

35. The method of claim 34, wherein the assembling further comprises lubricating the reservoir and piston with silicon fluid before insertion of the piston into the reservoir.

36. The method of claim 35, wherein the osmotic engine comprises osmotic tablets and polyethylene glycol adjacent the piston, and the assembling further comprises dispensing polyethylene glycol into the reservoir and inserting the osmotic tablets.

37. The method of claim 36, wherein after insertion of the osmotic tablets the semipermeable membrane is inserted into a first end of the reservoir adjacent the osmotic tablets.

38. The method of claim 37, wherein after insertion of the semipermeable membrane the suspension formulation is loaded into the reservoir through a second end of the reservoir.

39. The method of claim 38, wherein after loading of the suspension formulation the diffusion moderator is inserted into the second end of the reservoir.

41. A method of using the implantable osmotic drug delivery device of claim 26, the method comprising

implanting the osmotic drug delivery device in a subject, wherein the osmotic drug delivery device is not primed before implantation.

40. A method of making an implantable osmotic drug delivery device, the method comprising

lubricating a reservoir and a piston with silicon and inserting the piston into the reservoir;

dispensing polyethylene glycol into the reservoir and inserting osmotic tablets into the polyethylene glycol in the reservoir, wherein the osmotic tablets are adjacent the piston;

inserting a semipermeable membrane into a first end of the reservoir, wherein the semipermeable membrane is adjacent the osmotic tablets;

loading a suspension formulation into the reservoir through a second end of the reservoir, wherein the suspension formulation is a nonaqueous suspension formulation comprising

a particle formulation comprising an active agent and an excipient, wherein the active agent comprises a peptide, polypeptide, or protein, and the excipient comprises methionine or histidine, and

a nonaqueous, single-phase vehicle consisting essentially of about 10% to about 90% (w/w) polyvinylpyrrolidone and about 90% to about 10% (w/w) benzyl benzoate, wherein the vehicle has a viscosity of between approximately 10,000 poise to approximately 20,000 poise measured at 37°

C.; and

inserting a diffusion moderator into a second end of the reservoir, wherein the diffusion moderator is adjacent the suspension formulation.